X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
E7766 is a STING (Stimulator of Interferon Genes) agonist with broad specificity to all major genetic variants of human STING. Preclinical studies suggest that treatment with E7766 by intratumoral administration has anti-tumor activity at both local and systemic levels.
Lead Product(s): E7766
Therapeutic Area: Oncology Product Name: E7766
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
Details:
The presentations include interim data from H3’s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.
Lead Product(s): H3B-6545
Therapeutic Area: Oncology Product Name: H3B-6545
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
